[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tirzepatide\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tirzepatide":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100622759","clinical-and-neurobehavioral-changes-with-weight-loss-drug-discontinuation-and-reinitiation-100622759",false,"NCT07387796","Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation","Clinical and Neurobehavioral Changes With GLP-1 (Glucagon-like Peptide-1) Discontinuation","CLIN-GLP1","Inclusion Criteria:\n\n* Aged 18-70 years.\n* Currently on tirzepatide.\n* Currently receiving care from University of Texas- Southwestern (UTSW) Weight Wellness Clinic.\n* Cognitively capable of understanding and signing informed consent.\n* Be proficient in English.\n\nExclusion Criteria:\n\n* History of major neurological or psychiatric disorders, including substance use disorders that might confound brain imaging results (e.g., stroke, epilepsy, multiple sclerosis, schizophrenia, major depression requiring hospitalization).\n* Diagnosis of Type 2 Diabetes.\n* Current diagnosis of an eating disorder.\n* Use of medications affecting weight other than tirzepatide.\n* Pregnancy or breastfeeding.\n* MR contraindications:\n* Heart pacemaker, heart valve replacement, or aortic clips\n* Metal fragments in the eyes, skin, or elsewhere in the body\n* Brain clips or pieces of metal used in aneurysm surgery or intercranial bypass\n* Venous umbrella\n* Pieces of metal in the body resulting from work as a sheet-metal worker or welder\n* Clips placed in an internal organ\n* Prosthetic devices, such as middle ear, eye, joint, or penile implants\n* Joint replacement\n* Hearing aid that cannot be removed\n* Neurostimulator\n* Insulin pump\n* Shunts or stents\n* Metal mesh or coil implants\n* Metal plate, pin, screws, or wires, or any other metal implants","ALL","18 Years","70 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages 18-70 who are currently taking tirzepatide. Specifically, the study aims to examine how a short pause in tirzepatide affects hunger, mood, sleep, and daily functioning; how stopping and restarting tirzepatide alters brain chemistry and brain responses to food-related images; and how these changes relate to health measures such as quality of life and emotional well-being. There is no comparison group; instead, researchers will assess changes within each participant across three time points: while taking tirzepatide, after stopping it for 3-4 weeks, and after restarting it for 6-8 weeks. Participants will attend three in-person visits lasting approximately 3-4 hours each, during which they will complete interviews, questionnaires, and cognitive tasks; provide a urine sample (pregnancy screening for females); undergo a brain scan using magnetic resonance imaging (MRI) and MR spectroscopy (MRS); and receive a kit to provide a small stool sample. Participants will also complete two brief check-in phone calls between visits and the online BrainHealth Index between sessions, which includes surveys and cognitive tasks. All changes to tirzepatide use will occur under the supervision of a study physician to support participant safety and comfort, and the total study duration is approximately 13 weeks.",[28,29,30,31],"Drug Discontinuation","Substance Use Disorders","Eating Behavior Changes","Tirzepatide",[31,28,29,30],"RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":22},"2026-06",{"date":41,"type":22},"2029-02",{"name":43,"class":44},"The University of Texas at Dallas","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100639226","phase-4-tirzepatide-on-atrial-fibrillation-recurrence-after-catheter-ablation-in-patients-with-obesity-and-hfpef-100639226","NCT07630454","Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Obese and HFpEF: A Randomized Controlled Trial","TEAR-AF-HFpEF","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Symptomatic atrial fibrillation (paroxysmal or persistent of ≤ 5 years duration), undergoing first-time catheter ablation\n* Body weight criteria (aligned with NMPA-approved tirzepatide indication)，meeting at least one of the following:\n\n  * BMI ≥28.0 kg\u002Fm² (obesity threshold per Chinese criteria), OR\n  * BMI ≥24.0 kg\u002Fm² and \\\u003C28.0 kg\u002Fm² (overweight per Chinese criteria) with at least one weight-related comorbidity: hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM), obstructive sleep apnea syndrome (OSAS), or atherosclerotic cardiovascular disease (ASCVD)\n* HFpEF defined by intraprocedural mean left atrial pressure ≥ 15 mmHg at rest\n* Left ventricular ejection fraction ≥ 50% on echocardiography within 30 days prior to enrollment\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Prior use of any GLP-1 receptor agonist or GIP\u002FGLP-1 dual receptor agonist\n* Type 1 diabetes mellitus; or type 2 diabetes with HbA1c \\> 10%\n* Personal history of pancreatitis; personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)\n* Severe gastrointestinal disease, including gastroparesis or active inflammatory bowel disease\n* Prior bariatric surgery\n* Moderate or severe valvular heart disease, hypertrophic cardiomyopathy, cardiac amyloidosis, constrictive pericarditis, or restrictive cardiomyopathy\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Active malignancy, excluding basal cell carcinoma\n* Acute coronary syndrome, stroke, percutaneous coronary intervention, or cardiac surgery within 30 days prior to enrollment\n* Pregnancy, lactation, or planned pregnancy within 6 months\n* Life expectancy \\\u003C 12 months\n* Concurrent participation in another interventional clinical trial\n* Any condition that, in the investigator's judgment, would interfere with participation","80 Years",{"count":56,"type":22},602,[58],"PHASE4","This multicenter, randomized, open-label, blinded-endpoint trial evaluates whether weekly subcutaneous tirzepatide for 12 months reduces atrial fibrillation (AF) recurrence after catheter ablation in adults with obesity and heart failure with preserved ejection fraction (HFpEF). HFpEF is diagnosed by direct intraprocedural measurement of mean left atrial pressure (mLAP ≥ 15 mmHg at rest) during the ablation procedure, providing a hemodynamically anchored, homogeneous study population free from the diagnostic ambiguities of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and E\u002Fe' in AF patients. Approximately 602 participants will be randomized 1:1 to tirzepatide (titrated to a target of 10 mg\u002Fweek, maximum 15 mg\u002Fweek) plus standard care, or standard care alone. Both groups receive an identical structured lifestyle intervention. The primary endpoint is the first documented AF\u002Fatrial flutter\u002Fatrial tachycardia episode lasting ≥ 30 seconds, occurring between day 91 and day 365 after ablation, adjudicated by an independent blinded clinical endpoint committee.",[61,62,31],"Atrial Fibrillation","Heart Failure With Preserved Ejection Fraction (HFpEF)",[61,31,64,65,66],"GIP\u002FGLP-1 receptor agonist","Obesity","HFpEF","NOT_YET_RECRUITING","2026-06-03",{"date":70,"type":37},"2026-06-05",{"date":72,"type":22},"2026-08-01",{"date":74,"type":22},"2029-12-01",{"name":76,"class":44},"Yunlong Wang",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100625485","phase-4-tirzepatide-spartina-in-obese-kidney-transplant-recipients-100625485","NCT07423247","Tirzepatide (Spartina) in Obese Kidney Transplant Recipients","Safety and Efficacy of Tirzepatide (Spartina) in Obese Kidney Transplant Recipients: A Pilot Study on Weight Loss, Gastrointestinal Tolerability, and Graft Function","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Kidney transplant recipient with ≥12 months since transplantation\n* BMI ≥ 27 kg\u002Fm²\n* Stable graft function in the last 3 months (serum creatinine variation \\\u003C 20%)\n* Stable immunosuppressive regimen\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* History of pancreatitis\n* Severe gastroparesis\n* History of medullary thyroid carcinoma (MTC) or MEN2 syndrome\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²\n* Acute rejection episode within the past 6 months\n* Any condition judged by the investigator to interfere with study participation or safety",{"count":85,"type":22},30,[58],"Post-transplant obesity is a common complication after kidney transplantation, largely attributed to recovery from uremia, increased appetite, sedentary lifestyle, and long-term corticosteroid exposure. Obesity in kidney transplant recipients increases the risk of cardiovascular disease, post-transplant diabetes mellitus (PTDM), and may contribute to graft injury through hyperfiltration-related mechanisms, potentially leading to reduced graft survival. Current approaches for weight management in transplant recipients, including lifestyle modification, are often insufficient, while bariatric surgery carries considerable risks and concerns regarding altered absorption of immunosuppressive medications.\n\nTirzepatide (Iranian brand name: Spartina), the first dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated superior effects on weight reduction and glycemic control compared with earlier GLP-1 receptor agonists in the general population. However, its use in kidney transplant recipients requires careful evaluation due to potential gastrointestinal adverse effects, dehydration risk, and possible interaction with calcineurin inhibitor absorption caused by delayed gastric emptying.\n\nThis prospective single-arm pilot clinical trial aims to assess the preliminary safety and efficacy of tirzepatide in obese kidney transplant recipients with stable graft function. Outcomes include changes in anthropometric indices, percent weight change, gastrointestinal tolerability, immunosuppressive drug trough levels, and graft function over 24 weeks of treatment.",[31],"2026-02-13",{"date":91,"type":37},"2026-02-20",{"date":93,"type":37},"2026-01-01",{"date":95,"type":22},"2026-09",{"name":97,"class":44},"Shahid Beheshti University of Medical Sciences"]